BamSEC and AlphaSense Join Forces
Learn More

CTI BioPharma Corp

Formerly NASDAQ: CTIC

Material Contracts Filter

EX-10.2
from 10-Q 2 pages CTI BioPharma Corp. Amendment No. 2 to Severance Agreement
12/34/56
EX-10.1
from 10-Q 2 pages CTI BioPharma Corp. Amendment No. 2 to Employment Agreement [Remainder of Page Intentionally Left Blank.]
12/34/56
EX-10.3
from 10-Q 5 pages Material contract
12/34/56
EX-10.2
from 8-K 8 pages Amended and Restated 2007 Employee Stock Purchase Plan CTI BioPharma Corp
12/34/56
EX-10.1
from 8-K 13 pages Amended and Restated 2017 Equity Incentive Plan CTI BioPharma Corp
12/34/56
EX-10.47
from 10-K 11 pages Material contract
12/34/56
EX-10.3
from 8-K 2 pages Amendment to Severance Agreement
12/34/56
EX-10.2
from 8-K 10 pages Severance Agreement
12/34/56
EX-10.1
from 8-K 1 page In Addition, the Compensation Committee of the Board of Directors Has Granted You 210,000 Stock Options to Purchase Cti Common Stock. Such Options Shall Vest Over a Period of Four Years From Your Promotion Effective Date (Today), Wherein 25% or 52,500 Options Will Vest After Each Year From the Effective Date, Thus All 210,000 Options Shall Be Exercisable After Four Years. the Option Exercise Price Per Share Is the Last Quoted Per Share Selling Price for Shares on the Day of the Committee Meeting on September 23, 2021. Please Sign and Date a Copy of This Letter and Return It to Derald Lo in Hr. We Thank You for All the Contributions You Have Made at Cti and We Look Forward to Your Continued Success. Sincerely, Adam R. Craig, MD, Phd, Mba President, Chief Executive Officer & Interim Chief Medical Officer CTI BioPharma Corp (Cti) Acknowledgement: Signature: /S/ James K. Fong Date: March 1, 2022
12/34/56
EX-10.1
from 10-Q 61 pages Certain Information Has Been Omitted From This Exhibit in Places Marked “[***]” Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed or Because It Contains Personally Identifiable Information Omitted From This Exhibit Pursuant to Item 601(a)(6) Under Regulation S-K. Purchase and Sale Agreement by and Between CTI BioPharma Corp. and Drug Royalty III LP 2 Dated as of August 25, 2021
12/34/56
EX-10.2
from 8-K 11 pages Amended and Restated 2007 Employee Stock Purchase Plan CTI BioPharma Corp
12/34/56
EX-10.1
from 8-K 15 pages Amended and Restated 2017 Equity Incentive Plan CTI BioPharma Corp
12/34/56
EX-10.1
from 10-Q 2 pages CTI BioPharma Corp. Director Compensation Policy Effective March 10, 2021
12/34/56
EX-10.29
from 10-K 9 pages CTI BioPharma Corp. Stock Option Agreement
12/34/56
EX-10.1
from 10-Q 8 pages CTI BioPharma Corp. 2017 Equity Incentive Plan Stock Option Agreement
12/34/56
EX-10.46
from 10-K 2 pages CTI BioPharma Corp. Director Compensation Policy Effective March 13, 2019
12/34/56
EX-10.1
from 8-K 16 pages Amended and Restated 2017 Equity Incentive Plan CTI BioPharma Corp
12/34/56
EX-10.2
from 10-Q 2 pages CTI BioPharma Corp. Director Compensation Policy Effective March 13, 2019
12/34/56
EX-10.45
from 10-K 4 pages CTI BioPharma Corp. Executive Incentive Compensation Plan
12/34/56
EX-10.1
from 8-K 34 pages Termination and Transfer Agreement This Termination and Transfer Agreement (The “Termination and Transfer Agreement”) Is Effective as of November 1st, 2018 and Between Les Laboratoires Servier, a Company Duly Organized and Existing Under the Laws of France, Having Offices and Principal Place of Business at 50 Rue Carnot, 92284 Suresnes Cedex, France and Institut De Recherches Internationales Servier, a Company Duly Organized and Existing Under the Laws of France, Having Offices and Principal Place of Business at 50 Rue Carnot, 92284 Suresnes Cedex, France Together, Hereinafter Referred to as “Servier” on the One Hand, and CTI BioPharma Corp., a Corporation Organized and Existing Under the Laws of Delaware, Having Offices and Principal Place of Business at 3101 Western Ave., Suite 800, Seattle, Wa 98121, United States of America and Cti Life Sciences Limited, a Company Duly Organized and Existing Under the Laws of England, Having Offices and Principal Place of Business at Highlands House, Basingstoke Road, Spencers Wood, Reading, Berkshire Rg7 1nt, United Kingdom Together, Hereinafter Referred to as “Cti” on the Other Hand, Servier and Cti Being Hereinafter Individually Referred to as the “Party” and Collectively Referred to as the “Parties”. Recitals A. on September 16th, 2014 Servier and Cti Entered Into an Exclusive License and Collaboration Agreement (The “Original Agreement”) Pursuant to Which the Parties 1
12/34/56